AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC).
Ms. Stevens has served as a clinical consultant to Genprex since June 2018. In her new role, Ms. Stevens will lead clinical operations and support corporate development efforts, focusing on expanding research and clinical development opportunities, including the expansion of Genprex’s Oncoprex + Tarceva combination trial across multiple US sites.
“I am excited to join the Genprex team and work with various stakeholders to expand the clinical development program for Oncoprex,” said Ms. Stevens. “In addition to continuing the Phase I/II trial with Oncoprex in combination with Tarceva for NSCLC, we are working to advance additional combination treatments into human studies, such as Oncoprex plus checkpoint inhibitors.”
“We are pleased that Jan is joining our growing team in Cambridge, and believe that she will bring her broad experience in managing the clinical operations for our Oncoprex program,” said Julien L. Pham, MD, MPH, President and Chief Operating Officer of Genprex.
Ms. Stevens brings nearly 20 years of comprehensive clinical operations experience in the biopharma industry, with last the 10 years in a leadership role as a Vice President Clinical Operations, working at early to late stage oncology companies. Prior to joining Genprex, she served on senior management teams at BERG, LLC and ZIOPHARM Oncology, Inc., where she developed successful clinical strategies to advance small molecules and biologics from first-in-man studies to global pivotal trials. Prior to her work in clinical research, Ms. Stevens was an acute care nurse in the Neurology Unit at Massachusetts General Hospital. She received her RN degree with clinical affiliations from Massachusetts General Hospital, Brigham and Women’s Hospital, and Beth Israel Deaconess Hospital, and holds a Bachelor of Liberal Arts with concentration in Ethics, cum laude, from Harvard University.
Read more about Genprex’s Oncoprex immunogene therapy platform here.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex™ has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex™ has also been shown to block mechanisms that create drug resistance.